# A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

> **NCT03773666** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Oleclumab

## Key facts

- **NCT ID:** NCT03773666
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2021-02-04
- **Final completion:** 2021-08-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773666, "A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03773666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*